Ionq, Inc. current report, 25 May 2021

Full document

IonQ, Inc. (formerly DMY Technology Group, Inc. III) — Form 8-K Summary

Business context and reporting period

The filing concerns DMY Technology Group, Inc. III, a special purpose acquisition company associated with the company that later became IonQ, Inc. The report relates to an NYSE continued-listing notice received on May 25, 2021, and was signed and filed on June 1, 2021. The missing report was the Form 10-Q for the quarter ended March 31, 2021.

Key financial and operating metrics

The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating metrics. Those details were expected to be included in the delayed Q1 2021 Form 10-Q.

Material changes versus the prior comparable period

  • The NYSE notified the company that it was not complying with the exchange’s timely-filing requirement because the Q1 2021 Form 10-Q was not filed by May 24, 2021, including the extended period available under Rule 12b-25.
  • The company stated that it was assessing the impact of the SEC staff’s April 12, 2021 guidance concerning accounting and reporting for warrants issued by SPACs.
  • The company expected to file the Q1 2021 Form 10-Q as soon as practicable but did not provide a definitive filing date.

Outlook, risks, contingencies, and unusual items

  • The company could regain compliance by filing the Q1 2021 Form 10-Q with the SEC before November 24, 2021.
  • The delay was related to determining the accounting impact of the SEC’s SPAC warrant guidance on the company’s March 31, 2021 financial statements.
  • Failure to file within the cure period could create additional NYSE listing consequences; the filing text does not specify a delisting date or other penalty.
  • Management’s statement that it expected to file promptly is forward-looking and subject to delays, accounting issues, and other risks.

Important facts for investors to verify

  • Whether and when the delayed Q1 2021 Form 10-Q was ultimately filed.
  • The accounting treatment and valuation impact of the company’s warrants under the SEC’s April 12, 2021 guidance.
  • Whether the company regained compliance with NYSE continued-listing requirements.
  • The financial results, liquidity position, and any restatements or material adjustments disclosed in the eventual Form 10-Q.